Patents by Inventor DAVID JAMES MCMILLAN

DAVID JAMES MCMILLAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY
    Publication number: 20240076365
    Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 7, 2024
    Inventors: NEESHA DEDI, BREDA TWOMEY, MICHAEL JOHN WRIGHT, GARETH CHARLES GLYNDWR DAVIES, DAVID JAMES MCMILLAN
  • TAU-BINDING ANTIBODIES
    Publication number: 20230416350
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Application
    Filed: June 30, 2023
    Publication date: December 28, 2023
    Inventors: DAVID EDWARD ORMONDE KNIGHT, TERENCE SEWARD BAKER, DAVID JAMES MCMILLAN, ROBERT ANTHONY GRIFFIN, GEORGES MAIRET-COELLO, PATRICK DOWNEY, JEAN-PHILIPPE COURADE
  • Gremlin-1 crystal structure and inhibitory antibody
    Patent number: 11807680
    Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: November 7, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Neesha Dedi, Breda Twomey, Michael John Wright, Gareth Charles Glyndwr Davies, David James McMillan
  • Tau-binding antibodies
    Patent number: 11732034
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: August 22, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: David Edward Ormonde Knight, Terence Seward Baker, David James McMillan, Robert Anthony Griffin, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade
  • ARRAYS AND METHODS FOR IDENTIFYING BINDING SITES ON A PROTEIN
    Publication number: 20230176071
    Abstract: A method of identifying of amino-acid residues on a target protein that form a binding site of a molecule of interest. Such method relies on selection of relevant patches of solvent-accessible residues and testing of an array of mutated proteins for changes of binding properties. Such method is useful for determining binding sites (epitopes) of antibodies, ligands and related molecules.
    Type: Application
    Filed: May 6, 2021
    Publication date: June 8, 2023
    Inventors: Anastasios SPILIOTOPOULOS, David James MCMILLAN, Michael John Wright, Sebastian KELM, Xiaofeng LIU, Daniel John LIGHTWOOD
  • ANTIBODIES AGAINST KLK5
    Publication number: 20230075753
    Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory antibodies binding KLK5 and their use in the treatment of Netherton disease, atopic dermatitis and cancer.
    Type: Application
    Filed: February 1, 2021
    Publication date: March 9, 2023
    Inventors: Neesha DEDI, Peter Charles ELLIOTT, Seppe Frans Roman LEYSEN, Sean MASON, David James MCMILLAN, Gillian Claire NESS, Niccolo PENGO, Martin Anthony REDHEAD, Alison TURNER, Kerry Louise TYSON
  • ANTIBODIES AGAINST KLK5
    Publication number: 20230070261
    Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory anti-KLK5 antibodies and their use in the treatment of Netherton disease, atopic dermatitis and cancer.
    Type: Application
    Filed: February 1, 2021
    Publication date: March 9, 2023
    Inventors: Neesha DEDI, Peter Charles ELLIOTT, Seppe Frans Roman LEYSEN, Sean MASON, David James MCMILLAN, Gillian Claire NESS, Niccolo PENGO, Martin Anthony REDHEAD, Alison TURNER, Kerry Louise TYSON
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20220340648
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: February 28, 2022
    Publication date: October 27, 2022
    Inventors: Patrick DOWNEY, Kerry Louise TYSON, Marco KRIEK, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN, Peter Charles ELLIOT, Terence Seward BAKER
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20220220192
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: January 26, 2022
    Publication date: July 14, 2022
    Inventors: Ralph ADAMS, Patrick DOWNEY, Terence Seward BAKER, Kerry Louise TYSON, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN
  • Anti-alpha synuclein antibodies
    Patent number: 11292831
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: April 5, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Patrick Downey, Kerry Louise Tyson, Marco Kriek, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan, Peter Charles Elliott, Terence Seward Baker
  • Anti-alpha-synuclein antibodies
    Patent number: 11261242
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Patrick Downey, Terence Seward Baker, Kerry Louise Tyson, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan
  • GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY
    Publication number: 20210163586
    Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 3, 2021
    Inventors: NEESHA DEDI, BREDA TWOMEY, MICHAEL JOHN WRIGHT, GARETH DAVIES, DAVID JAMES MCMILLAN
  • MECHANISM OF ACTION
    Publication number: 20210140972
    Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 13, 2021
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, David James MCMILLAN, Graham John WARRELLOW, Daniel Christopher BROOKINGS, Rikki Peter ALEXANDER
  • TAU-BINDING ANTIBODIES
    Publication number: 20210115121
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 22, 2021
    Inventors: DAVID EDWARD ORMONDE KNIGHT, TERENCE SEWARD BAKER, DAVID JAMES MCMILLAN, ROBERT ANTHONY GRIFFIN, GEORGES MAIRET-COELLO, PATRICK DOWNEY, JEAN-PHILIPPE COURADE
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20210107971
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 15, 2021
    Inventors: Ralph ADAMS, Patrick DOWNEY, Terence Seward BAKER, Kerry Louise TYSON, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN
  • ANTI-ALPHA SYNUCLEIN ANTIBODIES
    Publication number: 20210101964
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 8, 2021
    Inventors: Patrick DOWNEY, Kerry Louise TYSON, Marco KRIEK, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN, Peter Charles ELLIOTT, Terence Seward BAKER
  • Gremlin-1 antibody
    Patent number: 10947304
    Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: March 16, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Neesha Dedi, Breda Twomey, Michael John Wright, Gareth Davies, David James McMillan
  • Tau-binding antibodies
    Patent number: 10889640
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 12, 2021
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Edward Ormonde Knight, Terence Seward Baker, David James McMillan, Robert Anthony Griffin, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade
  • Methods of identifying signaling modulators of the trimeric TNFa
    Patent number: 10883996
    Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: January 5, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, David James McMillan, Graham John Warrellow, Daniel Christopher Brookings, Rikki Peter Alexander
  • GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY
    Publication number: 20190330323
    Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 31, 2019
    Inventors: NEESHA DEDI, BREDA TWOMEY, MICHAEL JOHN WRIGHT, GARETH DAVIES, DAVID JAMES MCMILLAN